Skip to main content
Top
Published in: Inflammation 3/2013

01-06-2013

Epidermal Growth Factor Promotes Proliferation and Improves Restoration After Intestinal Ischemia–Reperfusion Injury in Rats

Authors: Yanxia Geng, Jieshou Li, Fan Wang, Qiurong Li, Xing Wang, Liqun Sun, Weiqin Li

Published in: Inflammation | Issue 3/2013

Login to get access

Abstract

Epidermal growth factor (EGF) is an attractive and promising therapeutic application for intestinal disorders. The current study examined its influence on proliferation and restoration after ischemia–reperfusion (I/R) injury in rat small intestine. Six groups were performed: sham operation (Con); ischemia for 30 min with subsequent reperfusion for 30 min (I/R); I/R injured with 500 μg/kg EGF injected 5 min before ischemia (Pre-l); I/R injured with 50 μg/kg EGF injected 5 min before ischemia (Pre-s); I/R injured with 500 μg/kg EGF injected 5 min after reperfusion (Post-l); and I/R injured with 50 μg/kg EGF injected 5 min after reperfusion (Post-s). Intestinal histological damage, crypt cell proliferation degree, mucosal permeability, tight junction proteins expression, and levels of inflammation factors were studied for each group. Compared with the I/R group, administration of EGF in the Pre-l, Pre-s, and Post-l groups all presented a significant proliferation effect. The levels of FD4, IL-6, and TNF-α were dramatically decreased in all EGF-treated groups. Histological destruction was improved and TJs recovery was notably accelerated in all EGF-treated groups except the Post-s group. d-lactate concentration was only diminished in the Pre-l group. These results suggest that mucosally applied EGF can promote intestinal proliferation and improve restoration after I/R injury. EGF intraluminal administration is an effective treatment against intestinal I/R injury.
Literature
1.
go back to reference Dominguez, J.A., and C.M. Coopersmith. 2010. Can we protect the gut in critical illness? The role of growth factors and other novel approaches. Critical Care Clinics 26: 549–565.PubMedCrossRef Dominguez, J.A., and C.M. Coopersmith. 2010. Can we protect the gut in critical illness? The role of growth factors and other novel approaches. Critical Care Clinics 26: 549–565.PubMedCrossRef
2.
go back to reference Carpenter, G., and S. Cohen. 1979. Epidermal growth factor. Annual Review of Biochemistry 48: 193–216.PubMedCrossRef Carpenter, G., and S. Cohen. 1979. Epidermal growth factor. Annual Review of Biochemistry 48: 193–216.PubMedCrossRef
3.
go back to reference Villa, X., J.W. Kuluz, C.L. Schleien, and J.F. Thompson. 2002. Epidermal growth factor reduces ischemia–reperfusion injury in rat small intestine. Critical Care Medicine 30: 1576–1580.PubMedCrossRef Villa, X., J.W. Kuluz, C.L. Schleien, and J.F. Thompson. 2002. Epidermal growth factor reduces ischemia–reperfusion injury in rat small intestine. Critical Care Medicine 30: 1576–1580.PubMedCrossRef
4.
go back to reference Berlanga, J., P. Prats, D. Remirez, et al. 2002. Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. American Journal of Pathology 161: 373–379.PubMedCrossRef Berlanga, J., P. Prats, D. Remirez, et al. 2002. Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. American Journal of Pathology 161: 373–379.PubMedCrossRef
5.
go back to reference Geng, Y., J. Li, Q. Li, and L. Sun. 2012. Role of proliferation in the recovery of intestinal mucosal function after ischemia–reperfusion injury in rats. Parenteral and Enteral Nutrition 19: 288–292. Geng, Y., J. Li, Q. Li, and L. Sun. 2012. Role of proliferation in the recovery of intestinal mucosal function after ischemia–reperfusion injury in rats. Parenteral and Enteral Nutrition 19: 288–292.
6.
go back to reference Chiu, C.J., A.H. McArdle, R. Brown, H.J. Scott, and F.N. Gurd. 1970. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Archives of Surgery 101: 478–483.PubMedCrossRef Chiu, C.J., A.H. McArdle, R. Brown, H.J. Scott, and F.N. Gurd. 1970. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Archives of Surgery 101: 478–483.PubMedCrossRef
7.
go back to reference Fujiyoshi, N., E. Feketeova, Q. Lu, D.Z. Xu, G. Hasko, and E.A. Deitch. 2006. Amiloride moderates increased gut permeability and diminishes mesenteric lymph-mediated priming of neutrophils in trauma/hemorrhagic shock. Surgery 140: 810–817.PubMedCrossRef Fujiyoshi, N., E. Feketeova, Q. Lu, D.Z. Xu, G. Hasko, and E.A. Deitch. 2006. Amiloride moderates increased gut permeability and diminishes mesenteric lymph-mediated priming of neutrophils in trauma/hemorrhagic shock. Surgery 140: 810–817.PubMedCrossRef
8.
go back to reference Murray, M.J., M.D. Gonze, L.R. Nowak, and C.F. Cobb. 1994. Serum D(-)-lactate levels as an aid to diagnosing acute intestinal ischemia. American Journal of Surgery 167: 575–578.PubMedCrossRef Murray, M.J., M.D. Gonze, L.R. Nowak, and C.F. Cobb. 1994. Serum D(-)-lactate levels as an aid to diagnosing acute intestinal ischemia. American Journal of Surgery 167: 575–578.PubMedCrossRef
9.
go back to reference Sun, X.Q., X.B. Fu, R. Zhang, et al. 2001. Relationship between plasma D(-)-lactate and intestinal damage after severe injuries in rats. World Journal of Gastroenterology 7: 555–558.PubMed Sun, X.Q., X.B. Fu, R. Zhang, et al. 2001. Relationship between plasma D(-)-lactate and intestinal damage after severe injuries in rats. World Journal of Gastroenterology 7: 555–558.PubMed
10.
go back to reference Grotz, M.R., E.A. Deitch, J. Ding, D. Xu, Q. Huang, and G. Regel. 1999. Intestinal cytokine response after gut ischemia: role of gut barrier failure. Annals of Surgery 229: 478–486.PubMedCrossRef Grotz, M.R., E.A. Deitch, J. Ding, D. Xu, Q. Huang, and G. Regel. 1999. Intestinal cytokine response after gut ischemia: role of gut barrier failure. Annals of Surgery 229: 478–486.PubMedCrossRef
11.
go back to reference Yang, R., X. Han, T. Uchiyama, et al. 2003. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. American Journal of Physiology–Gastrointestinal and Liver Physiology 285: G621–G629.PubMed Yang, R., X. Han, T. Uchiyama, et al. 2003. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. American Journal of Physiology–Gastrointestinal and Liver Physiology 285: G621–G629.PubMed
12.
go back to reference Meng, Z.H., K. Dyer, T.R. Billiar, and D.J. Tweardy. 2001. Essential role for IL-6 in postresuscitation inflammation in hemorrhagic shock. American Journal of Physiology. Cell Physiology 280: C343–C351.PubMed Meng, Z.H., K. Dyer, T.R. Billiar, and D.J. Tweardy. 2001. Essential role for IL-6 in postresuscitation inflammation in hemorrhagic shock. American Journal of Physiology. Cell Physiology 280: C343–C351.PubMed
13.
go back to reference Inoue, K., M. Oyamada, S. Mitsufuji, T. Okanoue, and T. Takamatsu. 2006. Different changes in the expression of multiple kinds of tight-junction proteins during ischemia–reperfusion injury of the rat ileum. Acta Histochemica et Cytochemica 39: 35–45.PubMedCrossRef Inoue, K., M. Oyamada, S. Mitsufuji, T. Okanoue, and T. Takamatsu. 2006. Different changes in the expression of multiple kinds of tight-junction proteins during ischemia–reperfusion injury of the rat ileum. Acta Histochemica et Cytochemica 39: 35–45.PubMedCrossRef
14.
go back to reference Feldman, G.J., J.M. Mullin, and M.P. Ryan. 2005. Occludin: structure, function and regulation. Advanced Drug Delivery Reviews 57: 883–917.PubMedCrossRef Feldman, G.J., J.M. Mullin, and M.P. Ryan. 2005. Occludin: structure, function and regulation. Advanced Drug Delivery Reviews 57: 883–917.PubMedCrossRef
15.
go back to reference Fanning, A.S., B.J. Jameson, L.A. Jesaitis, and J.M. Anderson. 1998. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. Journal of Biological Chemistry 273: 29745–29753.PubMedCrossRef Fanning, A.S., B.J. Jameson, L.A. Jesaitis, and J.M. Anderson. 1998. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. Journal of Biological Chemistry 273: 29745–29753.PubMedCrossRef
16.
go back to reference Dembinski, A., H. Gregory, S.J. Konturek, and M. Polanski. 1982. Trophic action of epidermal growth factor on the pancreas and gastroduodenal mucosa in rats. The Journal of Physiology 325: 35–42.PubMed Dembinski, A., H. Gregory, S.J. Konturek, and M. Polanski. 1982. Trophic action of epidermal growth factor on the pancreas and gastroduodenal mucosa in rats. The Journal of Physiology 325: 35–42.PubMed
17.
go back to reference Ulshen, M.H., L.E. Lyn-Cook, and R.H. Raasch. 1986. Effects of intraluminal epidermal growth factor on mucosal proliferation in the small intestine of adult rats. Gastroenterology 91: 1134–1140.PubMed Ulshen, M.H., L.E. Lyn-Cook, and R.H. Raasch. 1986. Effects of intraluminal epidermal growth factor on mucosal proliferation in the small intestine of adult rats. Gastroenterology 91: 1134–1140.PubMed
18.
go back to reference Goodlad, R.A., T.J. Wilson, W. Lenton, H. Gregory, K.G. McCullagh, and N.A. Wright. 1987. Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut 28: 573–582.PubMedCrossRef Goodlad, R.A., T.J. Wilson, W. Lenton, H. Gregory, K.G. McCullagh, and N.A. Wright. 1987. Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut 28: 573–582.PubMedCrossRef
19.
go back to reference Scheving, L.A., R.A. Shiurba, T.D. Nguyen, and G.M. Gray. 1989. Epidermal growth factor receptor of the intestinal enterocyte. Localization to laterobasal but not brush border membrane. Journal of Biological Chemistry 264: 1735–1741.PubMed Scheving, L.A., R.A. Shiurba, T.D. Nguyen, and G.M. Gray. 1989. Epidermal growth factor receptor of the intestinal enterocyte. Localization to laterobasal but not brush border membrane. Journal of Biological Chemistry 264: 1735–1741.PubMed
20.
go back to reference Alison, M.R., and C.E. Sarraf. 1994. The role of growth factors in gastrointestinal cell proliferation. Cell Biology International 18: 1–10.PubMedCrossRef Alison, M.R., and C.E. Sarraf. 1994. The role of growth factors in gastrointestinal cell proliferation. Cell Biology International 18: 1–10.PubMedCrossRef
21.
go back to reference Miller, C.A., and H.T. Debas. 1995. Epidermal growth factor stimulates the restitution of rat gastric mucosa in vitro. Experimental Physiology 80: 1009–1018.PubMed Miller, C.A., and H.T. Debas. 1995. Epidermal growth factor stimulates the restitution of rat gastric mucosa in vitro. Experimental Physiology 80: 1009–1018.PubMed
22.
go back to reference Clark, J.A., H. Gan, A.J. Samocha, A.C. Fox, T.G. Buchman, and C.M. Coopersmith. 2009. Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. American Journal of Physiology–Gastrointestinal and Liver Physiology 297: G471–G479.PubMedCrossRef Clark, J.A., H. Gan, A.J. Samocha, A.C. Fox, T.G. Buchman, and C.M. Coopersmith. 2009. Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. American Journal of Physiology–Gastrointestinal and Liver Physiology 297: G471–G479.PubMedCrossRef
23.
go back to reference Sullivan, P.B., P.J. Lewindon, C. Cheng, et al. 2007. Intestinal mucosa remodeling by recombinant human epidermal growth factor (1–48) in neonates with severe necrotizing enterocolitis. Journal of Pediatric Surgery 42: 462–469.PubMedCrossRef Sullivan, P.B., P.J. Lewindon, C. Cheng, et al. 2007. Intestinal mucosa remodeling by recombinant human epidermal growth factor (1–48) in neonates with severe necrotizing enterocolitis. Journal of Pediatric Surgery 42: 462–469.PubMedCrossRef
24.
go back to reference Palomino, A., F. Hernandez-Bernal, W. Haedo, et al. 2000. A multicenter, randomized, double-blind clinical trial examining the effect of oral human recombinant epidermal growth factor on the healing of duodenal ulcers. Scandinavian Journal of Gastroenterology 35: 1016–1022.PubMedCrossRef Palomino, A., F. Hernandez-Bernal, W. Haedo, et al. 2000. A multicenter, randomized, double-blind clinical trial examining the effect of oral human recombinant epidermal growth factor on the healing of duodenal ulcers. Scandinavian Journal of Gastroenterology 35: 1016–1022.PubMedCrossRef
25.
go back to reference Sinha, A., J. Nightingale, K.P. West, J. Berlanga-Acosta, and R.J. Playford. 2003. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. The New England Journal of Medicine 349: 350–357.PubMedCrossRef Sinha, A., J. Nightingale, K.P. West, J. Berlanga-Acosta, and R.J. Playford. 2003. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. The New England Journal of Medicine 349: 350–357.PubMedCrossRef
26.
go back to reference Sigalet, D.L., G.R. Martin, J.D. Butzner, A. Buret, and J.B. Meddings. 2005. A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. Journal of Pediatric Surgery 40: 763–768.PubMedCrossRef Sigalet, D.L., G.R. Martin, J.D. Butzner, A. Buret, and J.B. Meddings. 2005. A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. Journal of Pediatric Surgery 40: 763–768.PubMedCrossRef
27.
go back to reference Clark, J.A., S.M. Doelle, M.D. Halpern, et al. 2006. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. American Journal of Physiology–Gastrointestinal and Liver Physiology 291: G938–G949.PubMedCrossRef Clark, J.A., S.M. Doelle, M.D. Halpern, et al. 2006. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. American Journal of Physiology–Gastrointestinal and Liver Physiology 291: G938–G949.PubMedCrossRef
28.
go back to reference Clark, J.A., R.H. Lane, N.K. Maclennan, et al. 2005. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. American Journal of Physiology–Gastrointestinal and Liver Physiology 288: G755–G762.PubMedCrossRef Clark, J.A., R.H. Lane, N.K. Maclennan, et al. 2005. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. American Journal of Physiology–Gastrointestinal and Liver Physiology 288: G755–G762.PubMedCrossRef
29.
go back to reference Halpern, M.D., J.A. Dominguez, K. Dvorakova, et al. 2003. Ileal cytokine dysregulation in experimental necrotizing enterocolitis is reduced by epidermal growth factor. Journal of Pediatric Gastroenterology and Nutrition 36: 126–133.PubMedCrossRef Halpern, M.D., J.A. Dominguez, K. Dvorakova, et al. 2003. Ileal cytokine dysregulation in experimental necrotizing enterocolitis is reduced by epidermal growth factor. Journal of Pediatric Gastroenterology and Nutrition 36: 126–133.PubMedCrossRef
30.
go back to reference Berlanga-Acosta, J., J. Gavilondo-Cowley, P. Lopez-Saura, et al. 2009. Epidermal growth factor in clinical practice—a review of its biological actions, clinical indications and safety implications. International Wound Journal 6: 331–346.PubMedCrossRef Berlanga-Acosta, J., J. Gavilondo-Cowley, P. Lopez-Saura, et al. 2009. Epidermal growth factor in clinical practice—a review of its biological actions, clinical indications and safety implications. International Wound Journal 6: 331–346.PubMedCrossRef
Metadata
Title
Epidermal Growth Factor Promotes Proliferation and Improves Restoration After Intestinal Ischemia–Reperfusion Injury in Rats
Authors
Yanxia Geng
Jieshou Li
Fan Wang
Qiurong Li
Xing Wang
Liqun Sun
Weiqin Li
Publication date
01-06-2013
Publisher
Springer US
Published in
Inflammation / Issue 3/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9591-x

Other articles of this Issue 3/2013

Inflammation 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.